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Abstract
Background: Because few definitive markers are available for hepatic cancer stem cells (HCSCs), based on physical rather
than immunochemical properties, we applied a novel method to enrich HCSCs.
Methodology: After hepatic tumor cells (HTCs) were first isolated from diethylinitrosamine-induced F344 rat HCC model
using percoll discontinuous gradient centrifugation (PDGC) and purified via differential trypsinization and differential
attachment (DTDA), they were separated into four fractions using percoll continuous gradient centrifugation (PCGC) and
sequentially designated as fractions I–IV (FI–IV). Morphological characteristics, mRNA and protein levels of stem cell markers,
proliferative abilities, induced differentiation, in vitro migratory capacities, in vitro chemo-resistant capacities, and in vivo
malignant capacities were determined for the cells of each fraction.
Findings: As the density of cells increased, 22.18%, 11.62%, 4.73% and 61.47% of primary cultured HTCs were segregated in
FI–FIV, respectively. The cells from FIII (density between 1.041 and 1.062 g/ml) displayed a higher nuclear-cytoplasmic ratio
and fewer organelles and expressed higher levels of stem cell markers (AFP, EpCAM and CD133) than cells from other
fractions (P,0.01). Additionally, in vitro, the cells from FIII showed a greater capacity to self-renew, differentiate into mature
HTCs, transit across membranes, close scratches, and carry resistance to chemotherapy than did cells from any other
fraction; in vivo, injection of only 1610
4 cells from FIII could generate tumors not only in subcutaneous tissue but also in the
livers of nude mice.
Conclusions: Through our novel method, HCSC-like cells were successfully enriched in FIII. This study will greatly contribute
to two important areas of biological interest: CSC isolation and HCC therapy.
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Introduction
Over the last decade, the notion that tumors are maintained by
their own stem cells, the so-called cancer stem cells (CSCs), has
created great excitement in the research community [1]. CSCs are
generally dormant or slowly cycling tumor cells that have the
ability to reconstitute tumors [1]. They are thought to be involved
in tumor resistance to chemo/radiation therapy and tumor relapse
and progression. CSCs are important because they are responsible
for resistance to treatment. Obtaining further understanding of
CSC-specific traits will offer insights regarding the early stages of
tumorigenesis to aid in preventing this phenomenon and to
enhance the selectivity of antitumor therapies. The existence of
CSCs was first proposed over 40 years ago [2]; however, they were
only recently isolated from solid tumors, including tumors of the
breast [3], prostate [4], brain [5] and colon [6]. Although CSCs
have been isolated from some types of tumors, there is much
debate surrounding this topic.
Hepatocellular carcinoma (HCC) is a highly malignant type of
solid tumor associated with frequent metastasis and poor prognosis
[7]. Isolated hepatic CSCs (HCSCs) represent a suitable in vitro
model for developing therapeutic strategies aimed at eradicating
the tumorigenic subpopulation within HCC. It is for this reason
that the identification and understanding of HCSCs are crucial.
To isolate HCSCs, a variety of separation techniques are
available. One common method for isolating CSCs has been to
characterize their cell-surface phenotype and use markers to
negatively or positively select for particular cells. It is reported
hepatic tumor cells (HTCs) with the CD133+ or EpCAM+
phenotype have stem-like properties [8]; however, they have been
shown to exhibit limited plasticity. At present, a specific marker for
the isolation of HCSCs remains controversial. An alternative
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35720method for isolating HCSCs is urgently needed. Another method
for CSC separation is based on the differential efflux of fluorescent
dyes, such as rhodamine 123 or Hoechst 33342. Recently, the
isolation of side population (SP) cells using Hoechst 33342 dye has
become a useful method for obtaining CSCs from various tumors.
In a previous study by our group, we enriched HCSCs from the
MHCC97 cell line based on the efflux of rhodamine 123 or
Hoechst 33342 [9]. However, there are still some limitations
associated with this method, such as detecting false positive stem
cells and the requirement for special instruments. The final option
for the isolation of CSCs is based on physical separation methods,
such as density gradient separation. In a previous study, we
successfully isolated fetal liver stem/progenitor cells (FLSPCs)
from primary cultured fetal liver cells via density-gradient
centrifugation centered on a three-step method [10].
In the present study, we aimed to determine whether HCSCs
can be obtained by exploiting their physical properties. For this
purpose, we applied our established three-step method with a
slight adjustment for isolating HCSCs from primary HTCs. The
HTCs were first isolated using Percoll discontinuous gradient
centrifugation (PDGC), then purified based on differential
trypsinization and differential adherence (DTDA), and finally
layered by Percoll continuous gradient centrifugation (PCGC).
HTCs were thus separated into four subpopulations. The third
subpopulation, which contained the fewest cells, with a density
varying between 1.041 and 1.062 g/ml, showed the highest
expression of stem cell markers, the greatest ability to proliferate
and form colonies in vitro, the greatest capacity to migrate in vitro,
the strongest capacity to be resistant to chemotherapy, and the
richest ability to generate tumors in NOD/SCID mice. All of these
results indicated that the population from the third layer of the
PCGC gradients possessed CSC characteristics. This new strategy
for isolating HCSCs will make great contributions in two main
areas: it will provide new insights related to the isolation of other
kinds of CSCs; and it will allow us to investigate the contribution
of HCSCs to HCC.
Materials and Methods
1 Procedure for separating HTCs
1.1 Construction of an HCC model by diethylnitrosamine
(DEN) induction. Twelve male Fisher 344 rats (National
Rodent Laboratory Animal Resource, Shanghai, China) in the
trial group were treated with 0.05% DEN (Sigma Co, NY, USA)
in their drinking water for 6 weeks and were then switched to
normal drinking water [11]. Another twelve male Fisher 344 rats
in the control group were given a normal diet. At 10, 14 and 18
weeks after DEN induction, four rats from each group were
sacrificed. Samples of liver tissue from each group were routinely
processed and stained with hematoxylin and eosin (H&E) for
histological examination. All animal experiments were performed
strictly according to animal study protocols [12] and approved by
the Research Animal Care and Use Committee at the Fourth
Military Medical University.
1.2 Identification of HCC by immunohistochemistry. To
further identify the type of liver tumors that occurred in the rats,
the expression levels of AFP and CK19 were examined
immunohistochemically. Paraffin-embedded sections were
dewaxed using xylene and an ethanol concentration series,
blocked with 20% goat serum, and stained with a primary
rabbit-anti-rat AFP or CK-19 antibody (dilution 1:200; Santa
Cruz, CA). Goat anti-rabbit IgG secondary antibodies were used
for staining AFP or CK-19. These sections were also
counterstained with 2-(4-diamidinophenyl)-6-indolecarbamidine
dihydrochloride (DAPI) (dilution 1:100; Sigma) for detecting
nuclei. Negative controls were stained without primary
antibodies. Stained sections were examined under a fluorescent
microscope (FV1000MPE, Olympus Corporation, Tokyo, Japan).
The positive rates for AFP and CK-19 were determined in all
sections.
1.3 Isolation of HTCs by PDGC. Individual HCC nodules
were removed from each rat in the trial group. Raw HTCs were
isolated according to Hohne et al. [13] with minor modifications.
Briefly, the HCC nodules were minced in William’s E medium
(Sigma Co, Louis, MO, USA) with 0.1% collagenase type IV and
0.005% trypsin (Sigma Co, Louis, MO, USA) and then incubated
for 20 min at 37uC in a shaking water bath. After incubation, the
released cell supernatants were passed through a 100 mm nylon
mesh and centrifuged at 1,0006 g for 8 min. The pellets were
washed twice with phosphate-buffered saline (PBS) (Invitrogen Co,
USA) to obtain raw HTCs. These raw HTCs were prepared as
single cell suspensions and separated into different fractions using
PDGC (30%, 50% and 70% Percoll). The cells at the interface of
30% and 50% Percoll were collected and cultured in 6-well plates
containing William’s E medium supplemented with 10% vol/vol
fetal bovine serum (Invitrogen Co, USA), 5 mg/ml insulin (Sigma
Co, Louis, MO, USA), 5 mM hydrocortisone, 100 U/ml penicillin
and 100 mg/ml streptomycin at 37uC in a humidified atmosphere
containing 5% CO2. When the adherent cells extended as a
monolayer colony 20 days later, we collected the monoclonal cells
by local digestion with cloning cylinders and transferred them to a
new culture dish to continue the culturing process.
1.4 Purification of HTCs by DTDA. To obtain pure HTCs,
cells in culture were treated as follows. Based on the results of a
former study by our group [10], cells of different sizes can be
trypsinized within distinct time periods. It has been found when
the cells are digested using 0.25% trypsin for 10 min, very large
cells are trypsinized and excluded, whereas other cells remain.
This method is referred to as ‘‘differential trypsinization’’.
Interestingly, when the cells were completely trypsinized for
subculturing over a period of 120 min, large cells did not adhere to
the plates and were easily removed. This phenomenon is referred
to as ‘‘differential adherence’’. HTCs were purified via these two
stepsHTCs.
1.5 Separation of HTCs by PCGC. The protocol was
performed according to the methods of our previous study [10].
Briefly, to create continuous gradients, a 40% Percoll solution was
centrifuged at 20,0006g for 90 min using an angle head rotor.
The tube was then allowed to stand for 30 min, and the cell
suspension was gently layered on top of the preformed gradients.
The tube containing the cells was centrifuged at 5006g for 15 min
using a swinging bucket rotor. From the top to the bottom of the
tube, as the cell densities continuously increased, we collected four
cell fractions and designated them fractions I–IV (FI–IV)
(Figure 1A).
2 Morphological comparison among the different
fractions
2.1 Transmission electron microscopy (TEM). The
freshly isolated cells from each fraction were fixed with 2.5%
glutaraldehyde at 4uC for 4 h, then rinsed with cold PBS and
further fixed in 1% osmium tetroxide at room temperature for 2 h.
The samples were first dehydrated using a gradient of ethanol and
acetone, then embedded in Epon812 resin and acetone (v/v, 1:1)
for 30 min, followed by 100% Epon812 resin for 1 h. The
Epon812 resin was solidified at 37uC for 24 h and at 60uC for
48 h. Ultrathin sections were prepared using an LKB
ultramicrotome (Ultrotome NOVA; LKB, Broma, Sweden) and
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TEM (JEM-2000Ex, JEOL Ltd., Japan).
2.2 Immunofluorescence (IF) staining with
Phalloidin. To further analyze the morphological differences
among the freshly isolated cells from each fraction, phalloidin
staining was used. The cells were first treated with a primary
phalloidin antibody (dilution 1:100; Santa Cruz, CA) and then
with a fluorescent FITC-conjugated goat anti-rabbit secondary
antibody (dilution 1:100; Santa Cruz, CA) for 2 h. The gross
morphology of the cells was observed under a fluorescence
microscope, and the numbers of cilia and pseudopodia were
calculated.
3 Comparison of markers among different fractions
3.1 Flow cytometry (FCM). The freshly isolated cells from
each fraction were prepared at a concentration of 10
6cells/ml
using William’s E medium (containing 20% FBS) and incubated
for 15–30 min at room temperature to block non-specific sites.
These cells were then washed twice with PBS and re-suspended in
990 ml PBS. Subsequently, 10 ml of antibodies, including CD133
(PE-conjugated, Biolegend, USA) and EpCAM (FITC-conjugated,
Biolegend, USA), were added to each cell suspension. After
30 min of incubation at 4uC in the dark, the cells were washed
twice with PBS, fixed in 0.1% formaldehyde and analyzed using
the FACSCaliburTM system (BD Immunocytometry Systems, San
Jose, CA).
3.2 IF analysis. After the freshly isolated cells from each
fraction adhered to a culture slide, they were washed twice with
PBS, fixed with 4% paraformaldehyde for 20 min, and immersed
in PBS for 10 min, followed by exposure to 0.01% Triton X-100
at room temperature for 10 min. The cells were treated with 6%
goat serum (Santa Cruz, CA) at room temperature for 30 min to
block non-specific immune reactions and then with primary
CD133 (dilution 1:200; Santa Cruz, CA), AFP (dilution 1:200;
Santa Cruz, CA) and CK-19 (dilution 1:200; Santa Cruz, CA)
antibodies at 4uC overnight. After the samples were washed twice
with PBS, they were incubated with fluorescent PE/FITC-
conjugated goat anti-rabbit secondary antibodies (dilution 1:100;
Santa Cruz, CA) for 2 h. Subsequently, the samples were treated
with DAPI (dilution 1:100; Sigma) for 15 min. The fluorescence of
the samples was observed using a fluorescence microscope
(FV1000MPE, Olympus Co, Tokyo, Japan).
3.3 Quantitative real-time polymerase chain reaction
(qRT-PCR). Total RNA was extracted from the freshly
isolated cells of each fraction using the TRIzol reagent
(Molecular Research Center, Cincinnati, OH) and reverse
Figure 1. Formation of HCC and isolation of HTCs. (A) Small tumors (black arrows) were caused by 10 weeks of DEN induction. (B) The liver had
been almost completely replaced by large tumors 18 weeks after DEN induction. (C) Low magnification view of an H&E-stained section from tumor
tissue. (D) High magnification view of an H&E-stained section. (E) Low magnification view of an AFP-stained section. (F) High magnification view of an
AFP-stained section. (G) Low magnification view of a CK-19-stained section. (H) High magnification view of a CK-19-stained section. (I, J) Images of
primary cultured HTCs. (K, L) Images of HTCs purified by DTDA. Original magnifications: 1006(C, I–L), 2006(D, E, G), 4006(F, H).
doi:10.1371/journal.pone.0035720.g001
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according to the manufacturer’s instructions (Invitrogen, Carlsbad,
CA). An equal amount of cDNA from each sample was amplified
with specific primers (Table 1). PCR was carried out using SYBR
Green Master Mix (Applied Biosystems, Foster City, CA) over 40
cycles. The cycling parameters for the PCR were 10 minutes at
95uC, 15 seconds at 95uC, and 30 seconds at 60uC, with a final
dissociation step of 15 seconds at 95uC, 20 seconds at 60uC, and
15 seconds at 95uC using the Bio-Rad MyIQ5 real-time PCR
system (Bio-Rad, California, USA). Each sample was assayed in
triplicate. mRNA levels were normalized using GAPDH as an
internal reference.
4 The induced differentiation by hepatocyte growth
factor (HGF)
All the cells from each fraction were separately cultured in
commercial serum-free medium (Sigma Co, Louis, MO, USA)
supplemented with HGF at a concentration of 20 ng/ml. After all
the cells in 96-well plates (1610
3 cells/well) were cultured for 14 d,
they were collected and the exact identification was performed as
follows. The differentiation was evaluated by detecting the
expression of CSCs specific marker CD133 by FCM and HCC
marker AFP by IF. The detailed protocols were as described
above.
5 Functional comparison among different fractions
5.1 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) assay. The proliferative abilities of the freshly
isolated cells from each fraction were determined using the MTT
assay. Briefly, the cells were cultured in 96-well plates at a density
of 1610
3 cells/well. At 2, 4, 6, 8, 10, 12 and 14 days of culture,
MTT (Sigma, St. Louis, MO, USA) dissolved in PBS was added to
each well at a final concentration of 5 mg/ml, and the samples
were incubated at 37uC for 4 h. Water-insoluble dark blue
formazan crystals that formed during MTT cleavage in actively
metabolizing cells were then dissolved in dimethyl sulfoxide
(DMSO) (Gibco/Invitrogen, NY, USA). The optical density was
measured at a wavelength of 490 nm with a Bio-Rad 680
microplate reader (Bio-Rad, California, USA).
5.2 Colony formation test. The freshly isolated cells from
each fraction were inoculated separately into each well (10 cells
per well) of 96-well plates (Corning Life Sciences, Acton, MA)
supplemented with 100–200 ml of William’s E medium plus
leukemia inhibitory factor (LIF) at a concentration of 10 mg/ml.
Cell viability was assessed via staining with trypan blue (Sigma-
Aldrich) at several time points. After 4 weeks of culturing, each
well was examined using light microscopy, and the total number of
cell colonies was counted. Images of the colonies were recorded
using a microscope (Nikon Eclipse TS100, Nikon, Kingston-upon-
Thames, UK) and a digital camera (C4742-95, Hamamatsu
photonics, Welwyn Garden City, Hertfordshire, UK) under phase
contrast conditions.
5.3 Transwell migration assay. A total of 1610
5 cells in
0.5 ml of serum-free Williams’ E medium from each fraction were
seeded on an 8-mm pore-size polycarbonate membrane Boyden
chamber inserted in a transwell apparatus (Costar, Cambridge,
MA) coated with Matrigel. A total of 600 ml of Williams’ E
medium containing 20% FBS was added to the lower chamber.
After incubation for 24 h at 37uC in a 5% CO2 incubator, the cells
on the top surface of the insert were removed by wiping with a
cotton swab. The cells that had migrated to the bottom surface of
the insert were fixed in 100% methanol for 2 min, stained in 0.5%
crystal violet for 2 min, rinsed in PBS and subjected to inspection
via microscopy. Values for invasion and migration were obtained
by counting under an inverted light microscope (Olympus
Corporation, Tokyo, Japan) in 5 randomly selected fields.
5.4 In vitro scratch assay. Each well of 24-well tissue
culture plates was seeded with cells to a final density of 100,000
cells per well, and these cells were maintained at 37uC under 5%
CO2 for 24 h to allow them to adhere and to form confluent
monolayers. These confluent monolayers were then scored with a
sterile pipette tip to leave a scratch of approximately 0.4–0.5 mm
in width. The culture medium was then immediately removed
(along with any dislodged cells). The removed medium was
replaced with fresh William’s E medium. All scratch assays were
performed in triplicate. Scratch closure was monitored by
collecting digital images at the beginning of the experiment and
at regular intervals during the process of cell migration to close the
scratch, and the images were compared to quantify the migration
rate of the cells. Digital images were captured using an inverted
microscope (Nikon Eclipse TS100, Nikon, Kingston-upon-
Thames, UK) and a digital camera (C4742-95, Hamamatsu
photonics, Welwyn Garden City, Hertfordshire, UK) under phase.
5.5 Chemotherapeutic experiment. To confirm in vitro
chemo-resistance, 1.5610
5 cells from each fraction were plated in
24-well plates and treated with paclitaxel (10 ng/ml) for 24 h. The
optimal dose of paclitaxel used in this study was adopted according
to our preliminary experiments. An Annexin V-FITC/PI
apoptosis detection kit (Annexin V-FITC/PI Staining Kit;
Table 1. The primers used in the QRT- PCR.
Gene Name Sequence Tm (6C) Product length
CK-19 Forward aaccacgaggaggaaattagtg 59.5 225
Reverse tatctggatctgcgtagtgtgg 60.2
AFP Forward ctgtatgctcccaccattcttt 60.4 109
Reverse ttgatgctctctttgtctggaa 60.0
ALB Forward gacaaagcagcctgcctgac 63.4 174
Reverse ttctgcgaactcagcattgg 62.5
EpCAM Forward gtcattgtcgtggtggtgttag 60.3 109
Reverse cacccatctcctttatctcagc 60.1
GAPDH Forward atggtggtgaagacgccagta 55.5 143
Reverse ggcacagtcaaggctgagaatg 55.9
doi:10.1371/journal.pone.0035720.t001
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cell apoptosis. Briefly, the cells treated with paclitaxel were
collected, washed in cold PBS, incubated for 15 min with
fluorescein-conjugated annexin V and PI according to the
manufacturer’s protocols, and analyzed by FCM.
5.6 Tumor formation in NOD/SCID mice. Thirty-six
male NOD/SCID mice (6–8 weeks old) obtained from the
laboratory animal center of Beijing Xiehe Medical University
(Beijing, China) were maintained in pathogen-limited conditions at
the animal resources center of the Fourth Military Medical
University (Xi’an, China). These mice were randomly divided into
six groups: F0, FI, FII, FIII FIV, and the control HeG2 cell line.
Thus, each group was supplied with 6 mice. The cells were
injected into NOD/SCID mice via subcutaneous injection in
different amounts (1610
5 and 1610
4). Tumor growth was
monitored every 2 days after the second week of inoculation. All
mice were sacrificed 60 days after injection. All of the resultant
tumor tissues were collected, fixed in 4% formaldehyde, and
embedded in paraffin for H&E staining to assess tumor histology.
The tumors were classified according to their size. The existence of
no macroscopic tumor was defined as negative (2); a tumor
diameter of ,0.2 cm as positive (+); a diameter of 0.2–0.5 cm as
moderately positive (++); and a diameter of .0.5 cm as strongly
positive (+++).
6 Statistical analysis
SPSS 14.0 software was used for all statistical evaluations. All
data are expressed as the means 6 standard error of separate
experiments (n$3, where n represents the number of independent
experiments). The data were analyzed for statistical significance
using one-way ANOVA. P,0.05 was considered statistically
significant.
Results
1 HCC formation and HTCs isolation
When the rats were sacrificed 10 weeks after DEN induction,
only small tumors could be found (Figure 1A). At 18 weeks after
DEN induction, most of the liver tissue of the rats had been
replaced by tumor tissues with rough surfaces (Figure 1B). Based
on the assessments of three independent pathologists, H&E
staining verified that the tumors were all hepatic carcinoma
derived (Figure 1C, D). To further identify the type of the tumors,
we selected one marker for HCC (AFP) and another marker for
cholangiocarcinoma (CK-19) to stain tissue sections from the same
tumors. Most of the tumor cells within tumor nodules stained
positively for AFP (68.766.21%) (Figure 1E, F). In contrast,
almost no cells that stained positively for CK-19 were found over a
large area (1.1260.13%) (Figure 1G, H). In summary, the tumors
stained positively for AFP and negatively for CK-19. This finding
indicates that these tumors were almost hepatic origin, which is
consistent with the results of H&E staining. The HTCs isolated
from primary HCC tissues grew slowly at first, with only a few
colonies being formed, and displayed heterogeneous morphology
(Figure 1I, J). Through DTDA purification, HTCs proliferated
rapidly and were much more homogenous (Figure 1K, L). Thus,
these HTCs could be used for subsequent experiments.
2 Fractionation of HTCs by PCGC
In a former study, we found that centrifugation of 40% Percoll
for 90 min resulted in the formation of an optimal continuous
gradient [10]; therefore, in the present study, we applied this
methodology to fractionate HTCs. Under these conditions,
according to the distribution of cell pellets, we divided the HTCs
population (F0) into four main fractions (fraction I–IV, FI–IV).
Based on the monitoring of Density Marker Beads, four cell
fractions were gently removed individually from the tube, from the
top to the bottom (Figure 2A). Cell counting revealed that
22.1862.13%, 11.6261.06%, 4.7360.38% and 61.4766.24% of
the cells were segregated in FI–FIV, respectively, meaning that
FIV contained the most cells, and the fewest cells (less than 5%
cells) were found in FIII (Figure 2A). Based on dot-plot histograms
obtained from FACS, before separation, the cells in F0 were
heterogeneous in size, whereas after separation, the size of the cells
in each fraction became somewhat more homogenous. As
expected, FCM analysis of each subpopulation revealed an
increase in cell granularity [FSC (forward scatter)/SSC (side
scatter)] with increasing Percoll density (Figure 2B). Thus, from FI
to FIV, the cells continually increased in size.
3 Morphological comparison of cells from FI-FIV
The cells from each fraction were cultured separately in
William’s E medium. The cells from FIII were the first to adhere
to plates, which took place in less than 2 h, followed by the cells
from FI and FII in 2.5 h, and the cells from FIV and F0, which
required more than 3 h. Under in vitro culture conditions, the
heterogeneously sized cells in F0 could be easily observed. After
separation, it was found that the cells from FI and FII were the
smallest, followed by FIII, and the cells from FIV were the largest
(Figure 2C).
The TEM images displayed similar phenomena as observed in
the results obtained via light microscopy. The F0 cells exhibited a
great variety of diameters, ranging from 6 mmt o3 0 mm
(Figure 2D). The diameters of the cells from FI and FII were the
smallest, followed by FIII, and the diameters of cells from FIV
were the largest (Figure 2D). Meanwhile, the cells from FIII
presented the highest nuclear-cytoplasmic ratio and the fewest
organelles; in contrast, the cells from FIV showed the lowest
nuclear-cytoplasmic ratio and the most organelles (Figure 2D).
This indicated that the cells from FIII were the most immature.
In addition, we stained cells from each fraction using phalloidin.
Under fluorescence microscopy, the cells of FIII were slightly more
brightly stained by phalloidin and displayed more cilia or
pseudopodia on their surfaces than did the cells of any other
fraction (Figure 2E). However, the statistical analysis indicated the
difference was not significant (P.0.05).
4 Expression of stem cell markers
To determine the stem properties of cells in each fraction, two
relatively widely accepted stem cell markers were detected by
FCM immediately after separation. Both EpCAM and CD133
were most highly expressed in the freshly isolated cells from FIII
compared with the other fractions (P,0.01) (Figure 3A, C). The
percentage of EpCAM-positive cells in FIII was as high as
81.567.96%, and the percentage of CD133-positive cells was even
higher, at 84.768.53%. In contrast, the expression of both stem
cell markers in freshly isolated cells from FIV was lowest:
7.1%60.64% for EpCAM and 5.7%60.63% for CD133
(Figure 3A, C).
To further identify the stem properties of cells from each
fraction, we detected the expression of CD133 using IF. The
percentage of CD133-positive cells was the highest in FIII, at
83.2%68.01%, and the lowest in FIV, at 4.6%60.42%,
(Figure 3B, D). We also selected one hepatic tumor marker
(AFP) and one biliary tumor marker (CK-19) to identify cells from
each fraction. After segregation, the percentage of AFP-positive
cells in FIII was the highest (89.6%68.27%), being much higher in
any other fraction (P,0.01) (Figure 3B, D). However, only a few
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and almost no cells in F0, FII, FIII and FIV expressed CK-19
(Figure 3B, D).
The phenomenon described above was quantitatively verified
using qRT-PCR. The relative levels of EpCAM and AFP mRNA
were highest in cells from FIII (P,0.01), being nearly four times as
high as observed in cells from F0. In contrast, the EpCAM and
AFP mRNA levels were lowest in cells from FIV (P,0.01), being
half of the levels in cells from F0 (Figure 3E). In accord with the
results of IF, CK-19 mRNA could only be weakly detected in cells
from FI (relative fold was 0.10360.012); however, CK-19 mRNA
could barely be detected cells of F0, FII, FIII and FIV(Figure 3E).
Figure 2. Separation of HTCs and morphological comparison. (A) Schematic illustration of the continuous Percoll gradient used for
fractionation and the percentages of cells segregated in each fraction. (B) Dot-plot histograms resulting from FACS analysis showing the densities of
cells in each fraction. (C) Light microscopy of cells from each fraction under phase. (D) TEM images and diameters of cells from each fraction. (E)
Images of cell stained by phalloidin reflect the different morphologies of cell surfaces. Original magnifications: 1006(C), 60006(D), 4006(E).
doi:10.1371/journal.pone.0035720.g002
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35720Figure 3. Expression of specific markers in each cell fraction. (A) Expression of stem cell markers (EpCAM and CD133) in each fraction
determined by FCM. (B) Based on IF, CD133-positive cells (red, nuclei in blue) and AFP and CK-19-positive cells (green, nuclei in blue) were found to
be included in different proportions. (C) Column chart reflecting the data obtained via FCM. (D) Column chart reflecting the data generated by IF. (E)
qRT-PCR results of specific markers in freshly isolated cells from each fraction. F0 represents unfractionated HTCs; FI-IV indicates fractions I–IV after
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expressed in cells from FIV, very weakly expressed in cells from
F0, FI and FII, and expressed almost not at all in cells from FIII. It
can be speculated that the cells from FIII were much more
immature than cells from any other fraction (P,0.01).
5 The induced differentiation of cells from each fraction
Before induction, the cells from FIII were homogeneous in
morphology, when these cells were induced by HGF, they
proliferated very slowly, and many heterogeneous cells were
observed. Before induction, the cells from FIII expressed CSCs
marker CD133 (84.768.53%) higher than cells from other
fractions, 14 days after induction, the daughter cells from FIII
expressed CD133 as low as 28.763.02%, which was almost the
same as daughter cells from F0 and FI did (Figure 4A, C). In
addition, induced by HGF, the cells from FIII generated weak
AFP-positive cells. Although the percentage of AFP-positive cells
was still higher in daughter cells of FIII than in other fractions, the
daughter cells from FIII expressed AFP as low as 31.863.15%
(Figure 4B, C). That is to say, after induction the level of AFP
expression in FIII was decreased by 1.9 times. The above results
indicate that cells from FIII could be induced to lose CSCs-like
properties and differentiate into mature HTCs.
6 Proliferative abilities of cells from each fraction
One primary characteristic of CSCs is rapid proliferation.
During 7 days of culture, cells from FIII proliferated the most
rapidly, followed by cells from FI and F0, while cells from FII and
FIV proliferated slowest. Because there were the same number of
initial cells in each fraction, it was possible to observe in a column
chart of cell counts that beginning on the 4
th day, the number of
cells in FIII was much higher than in any other fraction (P,0.01)
(column charts shown in Figure 5A). Accordingly, the cell density
in FIII was the highest, and these cells were relatively more
homogeneous than cells from other fractions (light images in
Figure 5A). MTT assays showed that beginning on the 3
rd day, the
OD value generated by cells from FIII was higher than those
produced by cells from the other fractions, and the gap in OD
values between cells from FIII and cells from all other fractions
became increasingly larger (column charts in Figure 5B). This was
in strict agreement with what was observed in the grayscale images
of cells from each fraction on the 7
th day of culture (Figure 5B).
Another identifying characteristic of CSCs is their ability to
form cell colonies. Under the same culture conditions, the cells
from FIII formed colonies first, followed by cells from FI and F0,
and the cells from FII and FIV generated colonies the most slowly.
After 7 days of culture, not only the number of colonies but also
the average diameters of the colonies produced from each fraction
separation. * refers to P,0.01 compared with any other fraction. Original magnification: 1006(B).
doi:10.1371/journal.pone.0035720.g003
Figure 4. The differentiation of cells from each fraction induced by HGF. (A) Expression of stem cell marker CD133 in daughter cells from
each fraction determined by FCM. (B) Based on IF, AFP-positive cells (green) were found in daughter cells from each fraction. (C) Column chart reflects
the data of positive cells. F0 represents unfractionated HTCs; FI-IV indicates fractions I–IV after separation.
doi:10.1371/journal.pone.0035720.g004
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the cell colonies were as follows: 440 mm for F0, 400 mm for FI,
320 mm for FII, 680 mm for FIII, and 120 mm for FIV (Figure 5C).
Because the cells from FIII showed the greatest ability to form cell
colonies, it could be speculated these cells were more likely to be
HCSCs.
7 Migration abilities of cells
Based on the results of phalloidin staining, it was speculated the
cells of FIII would be a little more invasive than cells from other
fractions. The results of transwell assays indicated that under the
same incubation conditions, cells from FIII displayed significantly
higher transmembrane activity than did cells from any other
fraction (P,0.01). The percentage of cells that penetrated from
FIII was as high as 81.50%67.35%. In contrast, the percentage of
cells that transited the membrane among FIV cells was as low as
12.13%61.21% (Figure 5D). To shed further light on this
phenomenon, we performed scratch assays. Two days after
scratches were produced, although they were not closed by the
cells from any fraction, the closed percentage of the scratches
varied widely among the different fractions. Interestingly, the
percentage of closed scratches generated by cells from FIII, which
was 58.4%65.02% (Figure 5E), was much higher than that
produced by other fractions (P,0.01). These data demonstrate
Figure 5. Proliferative and invasive capacities of cells from each fraction. (A) Left panel: light images of cells from each fraction after 7 d
culture; right panel: column chart of cell counts during the cell culture period. (B) Left panel: gray images of cells from each fraction after 7 d culture;
right panel: results of MTT assays during the cell culture period presented in a column chart. (C) Left panel: gray images of cell colonies generated by
cells from each fraction; right panel: average diameters of cell colonies summarized in a column chart. (D) Left panel: light images of penetrating cells
from different fractions in transwell assays; right panel: average percentages of cells that crossed the membrane are shown using a column chart. (E)
Left panel: grayscale images of scratch assays showing the different abilities among cells from different fractions to close scratches via migration;
right panel: average percentages of closed scratches are provided in a column chart. (F) Left panel: the apoptotic analysis for cells from each fraction
by FCM; right panel: the percentages of apoptotic cells are shown by a column chart. F0 represents unfractionated HTCs; FI-IV indicates fractions I–IV
after separation. * refers to P,0.01 compared with any other fraction. Original magnification: 2006(A–D), 1006(E).
doi:10.1371/journal.pone.0035720.g005
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migration.
8 Resistance to chemotherapy
Because chemo-resistance is associated with CSCs-like pheno-
type [14], the cells from each fraction were evaluated by paclitaxel
treatment. We assessed the apoptotic rate of cells in each group
and summarized the results in Table 2. The results suggested that
there were significantly more normal cells and fewer apoptotic cell
from FIII than from any other fraction (P,0.01). The percentage
of apoptotic cells from FIII, including early and late apoptosis, was
as low as 13.50%61.21%. In contrast, the percentage of apoptotic
cells from FIV was as high as 36.91%63.18% (Figure 5F).
9 Tumorigenic potential of cells from each fraction
The growth of a subset of tumor cells (typically less than 5% of
total tumor cells) in immunodeficient mice has become the ‘‘gold
standard’’ for identifying CSCs [15]. To test the tumorigenic
ability of cells from each fraction, various numbers of cells were
injected into mice. After the number of tumors in each mouse was
counted, the size of each tumor was measured, and liver metastasis
in each mouse was examined; the data obtained from these
analyses are summarized in Table 3. Generally speaking, when
1610
5 cells were used, cells from F0, FI, FIII and HepG2 were
able to form tumors in every mouse; however, the same number of
injected cells from FII and FIV were able to generate tumors in
only half of the mice. Additionally, the average size of tumors
formed by cells from FIII was much larger than associated with
cells from any other group (P,0.01) (Figure 6A). Furthermore,
liver metastasis was most easily detected in mice injected with cells
from FIII (Table 3). When 1610
4 cells were used, xenograft
tumors were found within nearly every mouse injected with cells
from FIII, whereas the proportion of mice with tumors was 4/6 for
FI and HepG2, 3/6 for F0, and only 1/6 for FII and FIV (Table 3,
Figure 6B). As few as 1610
4 cells from FIII could initiate tumors
not only in subcutaneous tissues (Figure 6C, D) but also in liver
tissues of NOD/SCID mice (Figure 6F). Pathological analysis
indicated that the tumors from the subcutaneous regions
(Figure 6E) and tumors from livers (Figure 6G) were all hepatic
carcinoma derived. However, the same number of cells (1610
4)
from the HepG2 cell line did not cause damage to the liver,
including failing to generate tumors in liver tissue (Figure 6F, G) in
NOD/SCID mice. In summary, when the same number of cells
was used, cells from FIII caused larger tumors and more frequent
liver metastasis than did cells from the other fractions (P,0.01).
Discussion
Recent evidence indicates that tumors contain a small
population known as cancer stem cells (CSCs) that are responsible
for tumor initiation, maintenance and spreading [16]. The
American Association of Cancer Research Workshop working
group presented a consensus definition of the CSCs as ‘‘cells
within a tumor that possess the capacity for self-renewal and that
can cause the heterogeneous lineages of cancer cells that constitute
the tumor’’ [17]. Although the field of CSC biology is relatively
young, continued elucidation of the features of these cells holds
promise for the development of novel patient therapies [18].
Although evidence has been provided to support the existence of
CSCs in various solid tumors, the isolation of HCSCs has not been
clearly demonstrated.
Currently, various techniques based on the immunochemical
and physical characteristics of stem/progenitor cells are used for
enrichment of these cells types. Among these methods, FACS or
magnetic bead separation, which are both based on cell surface
markers, are most commonly used for either positive or negative
selection, respectively [19]. Among these markers, the same
specific marker can be used to isolate CSCs from different types of
cancers, whereas different markers can also be used to isolate
CSCs from the same types of cancers [20]. For example, EpCAM
is over-expressed in most solid cancers and has recently been
identified as a CSC marker [21]. CD133 is among the most useful
markers for the identification of CSCs, including those involved in
colorectal cancer [22], lung cancer [23], glioblastoma [24,25], and
thyroid cancer [26]. It appears that CD133 is a widely used
marker for CSCs; however, it is not highly specific for each kind of
cancer. For example, CD44 has been demonstrated to be more
specific than CD133 for isolating gastric cancer-initiating cells
from a panel of human gastric cancer cell lines [27]. However,
CD44 is still not generally applicable for CSC detection in many
cases [3,28–32]. In addition, it should be noted that there exist
some discrepancies regarding CSC markers among different
groups [6,29,33–40]. As recently reported [41], CD133 may not
be a true marker for colon CSCs, although two earlier studies
independently described CD133 as a good CSC marker for
colon cancer [6,35]. Thus, a single marker may not be sufficient
to isolate CSCs, and as a result, several markers are employed
together to isolate certain types of CSCs, such as CD44+
CD133+CD24+ cancer stem-like cells involved in murine
melanoma [42,43], CD133+CD34+ melanoma CSCs [44], and
CD133+/nestin+ lung cancer CSCs [45]. Furthermore, these
immunochemical methods present the disadvantages of being time
consuming and expensive because of the need to use monoclonal
antibodies and advanced technology. In addition, although greater
purity is obtained via immunological assays for isolating cells that
express a particular surface marker, the resulting cell populations
are still heterogeneous.
To avoid the above limitations, the alternative approach of
using SP cells has been applied for the enrichment of CSCs in
some organs and tissues [46], such as skeletal muscle, breast, liver,
small intestine, and uterus [47–51]. With respect to a possible
relationship between SP fractions and CSCs, an SP fraction was
also found associated with HCC [52]. Although SP cells have been
isolated from HCC, the association between the SP fraction and
HCSCs has not been confirmed. Furthermore, as reported by
other investigators [53], we observed that Hoechst 33342 staining,
which is used in FACS to isolate SP cells, was harmful to HTCs
[9]. Therefore, non-SP cells may also harbor cancer stem-like cells.
These results imply the limitation of using SP cells from HCC for




apoptosis Late Apoptosis Necrosis
F0 73.5662.16* 21.5461.02* 4.1860.32 0.6260.03
FI 79.4562.29 15.5561.13 4.4360.34 0.4760.02{
FII 56.5462.21* 29.0661.06* 7.2860.52* 7.1260.64*
FIII 86.1262.14 11.0960.86 2.4260.58 0.3860.02
FIV 58.0062.05* 22.1061.16* 14.8161.18* 5.1960.35*
Note:
*P,0.01 compared to FIII;
{P.0.05 compared to FIII.
doi:10.1371/journal.pone.0035720.t002
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PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e35720Figure 6. Tumorigenic and invasive potential of cells from each fraction. (A) Column chart showing the tumor incidence in each group
following the injection of 1610
5 cells. (B) Column chart showing the tumor incidence in each group following the injection of 1610
4 cells. (C)
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be sought to isolate HCSCs.
The physical separation of CSCs remains a good alternative.
Similar to the results of another study [54], we hypothesized that
the unique features of CSCs may allow them to be isolated based
on their specific morphology. Because HTCs exhibit different
levels of granularity, we considered the possibility of exploiting
properties related to density to separate these cells. Density-
gradient centrifugation (DGC) is an established physical method
for separation that has been used for years by investigators to
facilitate the isolation of different cell types [55]. Percoll has been
determined to be an ideal medium for these experiments, as it is a
well-known reagent that is relatively inexpensive and easy to
acquire [56]. This medium can be diluted to produce a wide range
of densities without difficulty. As HCSCs had not previously been
characterized based on density, we applied our established three-
step method [10] for enriching HCSCs. HTCs were first isolated
using PDGC, purified via DTDA, and finally separated into four
fractions with PCGC. To verify the efficiency of our method, we
examined the self-renewal and multiple potentials of cells from
each fraction. All of the results of these analyses showed a
preferential distribution of CD133 and EpCAM in a population
characterized by a density between 1.041 and 1.062 g/ml (FIII),
which included most CSC-like cells.
More specific isolation of HCSCs will shed new light not only
on the cellular origin of HCC but also on the underlying biological
mechanisms associated with this specific CSC population, which
will ultimately lead to the development of more specific
therapeutic agents for the treatment of this deadly cancer [43].
Three years ago, we found that reactivated CD133-positive cells
were frequently present in HCC [57], corresponding to later-stage
tumors. Subsequently, several studies used CD133 to isolate
HCSCs [58–61]. To date, although several possible markers for
HCSCs, including CD133 [22,58–61], EpCAM [8,21,62], CD90/
CD44 [61], DLK [63], CD24 [62,64], CD13 [65] and OV6 [66],
have been used to isolate putative CSCs from HCC in different
studies, it is unknown which of these may be a ‘‘one-fits-all’’
marker for CSCs in HCC. Therefore, the presence of markers
alone should be viewed with caution in isolating HCSCs
[60,62,67].
In this study, we developed a novel methodology that allowed
efficient enrichment of CSCs from primary cultures of HTCs. To
ensure the purity of HTCs, we employed DTDA to remove non-
target cell types. Using PCGC, a small subset of HTCs (less than
5% of total HTCs) was enriched in FIII, where the density ranged
from 1.041 to 1.062. These cells were observed to resemble CSCs
in many aspects. First, these cells possessed the capacities of self-
renewal and to form cell colonies derived from single parental
cells. The morphology of cells from FIII was similar to CSCs, such
as exhibiting high nuclear-cytoplasmic ratio, few organelles, many
cilia or pseudopodia, cellular pleomorphism, and hyperchromatic
nuclei. Second, the cells from FIII expressed high levels of stem
cell markers, such as AFP, EpCAM and CD133. Third, the cells
from FIII could greatly differentiate into mature HTCs by HGF
induction. Fourth, based on scratch assays and transwell assays,
the cells from FIII showed the greatest capacity to close scratches
and penetrate wells, indicating that these cells were most likely to
migrate. Fifth, through chemotherapeutic experiment, the cells
from FIII were most resistant to paclitaxel, which might be
associated with CSCs-like phenotype. Finally, using the ‘‘gold
standard’’ to identify CSCs [15], the cells from FIII showed the
greatest ability to form tumors in both subcutaneous and liver
tissues in immunodeficient mice. Taken together, our findings
confirmed that FIII contained a population of cells with
characteristics resembling those of CSCs. The cells from FIII
were potentially cancer stem-like cells with characteristics of in vitro
Table 3. The tumorigenic potential of cells from each fraction.
Cell subpopulations Tumor incidence Tumor diameter Metastasis incidence
F0 (1610
5) 6/6 ++ 2/6
FI (1610
5) 6/6 ++ 2/6
FII (1610
5) 3/6 + 0/6
FIII (1610
5)* 6/6 +++ 6/6
FIV (1610
5) 3/6 + 0/6
HepG2 (1610
5) 6/6 ++ 0/6
F0 (1610
4) 3/6 +,++ 2/6
FI (1610
4) 4/6 +,++ 2/6
FII (1610
4) 1/6 2,+ 1/6
FIII (1610
4)* 6/6 +++ 5/6
FIV (1610
4) 1/6 2,+ 1/6
HepG2 (1610
5) 4/6 ++ 0/6
‘‘Tumor incidence’’ indicates the average incidence of tumors in each mice (6 mice in each group, 6/6 means 6 tumors in 6 injected mice). ‘‘Tumor diameter’’ refers to
the average diameter of tumors in each group (2, no macroscopic tumor; +, ,0.2 cm; ++, 0.2–0.5 cm; +++, .0.5 cm). ‘‘Metastasis incidence’’ means the average
incidence of the liver neoplasia in each group (6/6 means 6 liver neoplasias found in 6 mice). All results were independently viewed by three different researchers.
*FIII vs. F0, FI, FII, FIV (the same number), P,0.01.
doi:10.1371/journal.pone.0035720.t003
Subcutaneous tumors in mice following the implantation of 1610
4 cells from each group. (D) Representative tumors were selected accordingly. (E)
Histological analysis of subcutaneous tumors by H&E staining, showing HCC-specific features (irregularly packed tumor cells, hyperchromatic nuclei,
high density of microvessels and pleomorphism). (F) The livers of the mice were damaged to different extents by injecting 1610
4 cells from each
group (black arrows). (G) H&E staining of liver lesions. Original magnification: 2006(E, G).
doi:10.1371/journal.pone.0035720.g006
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tumorigenic capacity.
Conclusions
In conclusion, we have shown that HTCs within the moderate-
density interface between 1.041 and 1.062 g/ml contained cells
with stem-like properties. Although these enriched cells might be
heterogeneous, they contained a greater amount of HCSCs. The
method described in the present paper provides an alternative to
existing separation methods (FACS, MACS, SP) for the isolation
of HCSCs. We anticipate that this study will encourage and enable
investigators to move forward in HCSC research, which will aid in
exploring the composition and origin of HCSCs and the molecular
mechanisms underlying their genesis.
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